Brief: Ligand Announces Proposed Offering Of $550 Million Of Convertible Senior Notes Due 2031
22/06/2026 12:49
BRIEF-Ligand Announces Proposed Offering Of $550 Million Of Convertible Senior Notes Due 2031 June 22 (Reuters) - Ligand Pharmaceuticals Inc LGND.O:
LIGAND ANNOUNCES PROPOSED OFFERING OF $550 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2031
LIGAND PHARMACEUTICALS - TO USE PART OF PROCEEDS FOR CONVERTIBLE NOTE HEDGE TRANSACTIONS
LIGAND PHARMACEUTICALS - TO USE UP TO $75 MILLION OF PROCEEDS FOR COMMON STOCK REPURCHASE
LIGAND PHARMACEUTICALS - INITIAL PURCHASERS GRANTED 13-DAY OPTION TO BUY UP TO $82.5 MILLION ADDITIONAL NOTES
Source text: ID:nGNXc10Y4D
Further company coverage: LGND.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ligand Pharmaceuticals Incorporated
See all newsBrief: Ligand Acquires Royalty And Milestone Interest In Santen’s Ryjunea From Sydnexis For $23 Million
Ligand Pharmaceuticals Incorporated reports results for the quarter ended June 30 - Earnings Summary
Ligand Pharmaceuticals Q2 revenue rises on royalty growth
Brief: Ligand Pharmaceuticals Q2 EPS USD 2.22
U.S. RESEARCH ROUNDUP-Equinix, Goldman Sachs, JPMorgan